The Appointment Of Clay B. Siegall To The Board Of Mirna Therapeutics Inc.

The Appointment Of Clay B. Siegall To The Board Of Mirna Therapeutics Inc.

Mirna Therapeutics has appointed Clay B. Siegall, Ph.D. to its Board of Directors. It is a firm that is involved in biotechnology and focuses on developing as well as commercializing these microRNA (miRNA) therapeutics.

Clay B. Siegall, Ph.D., is presently the co-founder along with the President of Seattle Genetics. He is serving as its Chief Executive Officer and the Chairman of its Board of Directors.

He has a lot of experience in the pharmaceutical industry. Besides, he has won a lot of accolades in building an oncology firm that is highly successful. The Mirna team will be making use of all these attributes as it advances in developing several therapeutic that are based on microRNA.

As per Clay B. Siegall, this microRNA-based therapeutics presents a new, exciting field of cancer research. Thus he thinks that Mirna is well-placed since it has a strong pipeline which has several product candidates. Hence he looks forward to teaming up with them as he advances their programs for all those patients who are in need of such programs.

  1. Clay Siegall is providing his unique leadership to this firm. It comprises of a diverse pipeline of distinct therapies. All of these are based on antibodies which have been developed by this company to address the varying medical requirements of patients suffering from cancer.

Its first commercial product was ADCETRIS® (brentuximaesid vedotin). It was in 2011 that it got approved. There are a number of other products that are already in the pipeline of this company.

Seattle Genetics enters into several other strategic collaborations too. They are with leading biotechnology along with pharmaceutical companies that are working in the field of oncology.

Clay B. Siegall looks into the activities relating to capital raise for Seattle Genetics. This way $675 million have been secured. It is through public financings and even private ones too. In 2001, he even directed the initial public offering of this company. He is also on the Board of Directors of another company, namely, Alder BioPharmaceuticals, which is a private, company working in the field of biotechnology. Hence Clay is the right person to lead this company.

 

Comments are closed.